КР Хронический вирусный гепатит В

56.Perillo R, Buti M, Durand F, et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transplant 2013; 19:887-95.

57.Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (обновленная версия от 31.07.2013 на http://aidsinfo.nih.gov/guidelines).

58.Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAgnegative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-61.

59.Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAgnegative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56:1006-11.

60.Sanchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-56.

61.Sheu JC, Huang GT, Shih LN, et al. Hepatitis C and B virus in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103:1322-7.

62.Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: precore/core mutation may play an important role. J Med Virol 2000; 60(3):249-55.

63.Tan HH, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int 2008; 2(3):370-5.

64.Teperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Pungpapong S, et al. Emtricitabine/tenofovir DF combination +/- HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. J Hepatol 2010; 52:12-3.

65.Uemoto S., Sugiyama K., Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65:494-9.

66.Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16:94-103.

67.Weinbaum CM, Williams I, Mast EE, et al. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8):1-20.

68.WHO position paper on Hepatitis B vaccines October 2009. World Health Organization. Summary of Key Points, N 1.

69.Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13:211-20.

70.World Health Organization. Hepatitis B Fact sheet, July 2012. Available at: http://www.who.int/mediacentre/ factsheets/fs204/ en/. Accessed November 1, 2012.

71.Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection:72.

72.Yang YB, Li XM, Shi ZJ, et al. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J Gastroenterol 2004; 10(6):2305-6.

73.Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39:1694-701.